Emerging role of MicroRNA-Based theranostics in Hepatocellular Carcinoma

Mol Biol Rep. 2023 Sep;50(9):7681-7691. doi: 10.1007/s11033-023-08586-z. Epub 2023 Jul 7.

Abstract

Hepatocellular carcinoma (HCC), with its high mortality and short survival rate, continues to be one of the deadliest malignancies despite relentless efforts and several technological advances. The poor prognosis of HCC and the few available treatments are to blame for the low survival rate, which emphasizes the importance of creating new, effective diagnostic markers and innovative therapy strategies. In-depth research is being done on the potent biomarker miRNAs, a special class of non-coding RNA and has shown encouraging results in the early identification and treatment of HCC in order to find more viable and successful therapeutics for the disease. It is beyond dispute that miRNAs control cell differentiation, proliferation, and survival and, depending on the genes they target, can either promote tumorigenesis or suppress it. Given the vital role miRNAs play in the biological system and their potential to serve as ground-breaking treatments for HCC, more study is required to fully examine their theranostic potential.

Keywords: Angiogenesis; Cell proliferation; Hepatocellular carcinoma; Invasion; miRNA.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Biomarkers, Tumor / analysis
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / drug therapy
  • Cell Proliferation
  • Humans
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / drug therapy
  • MicroRNAs* / analysis
  • MicroRNAs* / antagonists & inhibitors
  • Neoplasm Metastasis
  • Neovascularization, Physiologic

Substances

  • MicroRNAs
  • Biomarkers, Tumor